{"title":"Readiness to Implement Novel SACT: Tumor-Infiltrating Lymphocyte Therapy.","authors":"Linda Gomm","doi":"10.1016/j.soncn.2025.151841","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) therapy has demonstrated promising results in clinical trials. Recognizing the growing potential of cell therapies for solid tumors, oncology services need to prepare for an increasing number of trials and, in the near future, optimize patient access to TIL. Consultation with clinical trials professionals in England, however, highlighted low organizational readiness and significant knowledge gaps for use of adoptive cell therapy. The aim of this discussion paper is to provide guidance about the role of the nurse in the delivery of TIL therapy.</p><p><strong>Methods: </strong>Guidance was written based on peer-reviewed literature and best practice guidelines between 2006 and 2024 identified through electronic database searches on PubMed, CINAHL, and MEDLINE and expert experience of managing patients in clinical trials who are receiving TIL.</p><p><strong>Results: </strong>TIL therapy is set to transform current care pathways with treatments that can potentially induce long-lasting tumor responses. There are, however, numerous challenges for successful and safe implementation of TIL therapy in practice. Nurses have a central role in coordinating the safe delivery and patient care of patients receiving TIL therapy. Nurses need knowledge and understanding about the regulatory processes and extensive treatment pathways involved whilst also managing novel side effects and patient expectations.</p><p><strong>Conclusions: </strong>TIL therapy requires a specialist team to safely deliver these complex treatments and support colleagues nursing patients receiving TIL therapy. Specialist knowledge and skills and close coordination is required to ensure a smooth process from patient referral, product ordering, manufacturing, storage, and administration of the treatment to the patient.</p><p><strong>Implications for nursing practice: </strong>Organizations planning to initiate TIL therapy should review their infrastructure, identify and address specialist knowledge and skills needs of oncology professionals, and seek guidance and support from expert teams. There needs to be a robust governance structure in place and ensure all healthcare professionals involved are trained and educated on a high level on how to care for these patients.</p>","PeriodicalId":54253,"journal":{"name":"Seminars in Oncology Nursing","volume":" ","pages":"151841"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Oncology Nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.soncn.2025.151841","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0
摘要
目的:采用肿瘤浸润淋巴细胞(TIL)疗法的适应性细胞疗法在临床试验中取得了良好的效果。由于认识到细胞疗法治疗实体瘤的潜力越来越大,肿瘤服务部门需要为越来越多的试验做好准备,并在不久的将来优化患者获得 TIL 的途径。然而,对英国临床试验专业人员的咨询结果表明,采用细胞疗法的组织准备程度很低,知识差距也很大。本讨论文件旨在为护士在 TIL 治疗中的作用提供指导:方法:根据PubMed、CINAHL和MEDLINE等电子数据库搜索到的2006年至2024年间的同行评议文献和最佳实践指南,以及专家在临床试验中管理接受TIL患者的经验,撰写了指南:结果:TIL疗法将改变目前的治疗路径,其治疗方法有可能诱导持久的肿瘤反应。然而,要在实践中成功、安全地实施 TIL 疗法,还面临着诸多挑战。护士在协调接受 TIL 疗法患者的安全治疗和患者护理方面发挥着核心作用。护士需要了解和理解相关的监管流程和广泛的治疗途径,同时还要处理新的副作用和患者的期望:TIL疗法需要一个专业团队来安全实施这些复杂的治疗,并为护理接受TIL疗法患者的同事提供支持。需要专业知识和技能以及密切协调,以确保从患者转诊、产品订购、生产、储存到患者接受治疗的整个过程顺利进行:计划启动 TIL 疗法的机构应审查其基础设施,确定并满足肿瘤专业人员对专业知识和技能的需求,并寻求专家团队的指导和支持。需要建立健全的管理结构,并确保所有参与其中的医护人员都接受过如何护理这些患者的高水平培训和教育。
Readiness to Implement Novel SACT: Tumor-Infiltrating Lymphocyte Therapy.
Objectives: Adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) therapy has demonstrated promising results in clinical trials. Recognizing the growing potential of cell therapies for solid tumors, oncology services need to prepare for an increasing number of trials and, in the near future, optimize patient access to TIL. Consultation with clinical trials professionals in England, however, highlighted low organizational readiness and significant knowledge gaps for use of adoptive cell therapy. The aim of this discussion paper is to provide guidance about the role of the nurse in the delivery of TIL therapy.
Methods: Guidance was written based on peer-reviewed literature and best practice guidelines between 2006 and 2024 identified through electronic database searches on PubMed, CINAHL, and MEDLINE and expert experience of managing patients in clinical trials who are receiving TIL.
Results: TIL therapy is set to transform current care pathways with treatments that can potentially induce long-lasting tumor responses. There are, however, numerous challenges for successful and safe implementation of TIL therapy in practice. Nurses have a central role in coordinating the safe delivery and patient care of patients receiving TIL therapy. Nurses need knowledge and understanding about the regulatory processes and extensive treatment pathways involved whilst also managing novel side effects and patient expectations.
Conclusions: TIL therapy requires a specialist team to safely deliver these complex treatments and support colleagues nursing patients receiving TIL therapy. Specialist knowledge and skills and close coordination is required to ensure a smooth process from patient referral, product ordering, manufacturing, storage, and administration of the treatment to the patient.
Implications for nursing practice: Organizations planning to initiate TIL therapy should review their infrastructure, identify and address specialist knowledge and skills needs of oncology professionals, and seek guidance and support from expert teams. There needs to be a robust governance structure in place and ensure all healthcare professionals involved are trained and educated on a high level on how to care for these patients.
期刊介绍:
Seminars in Oncology Nursing is a unique international journal published six times a year. Each issue offers a multi-faceted overview of a single cancer topic from a selection of expert review articles and disseminates oncology nursing research relevant to patient care, nursing education, management, and policy development.